cjc 1295 dac

Overview of CJC 1295 DAC: Molecular Structure and Pharmacokinetics

The cjc 1295 dac peptide is a modified 30-amino acid GHRH derivative that incorporates a bioconjugating Drug Affinity Complex (DAC) linked to the C-terminus. By utilizing a reactive maleimidopropionic acid moiety, the compound covalently binds to circulating serum albumin following administration in laboratory models. This albumin-binding mechanism shields the peptide from rapid enzymatic degradation by dipeptidyl peptidase IV (DPP-IV) and renal clearance, extending the terminal elimination half-life from minutes to approximately 6 to 8 days in non-human subjects.

Engineered through targeted amino acid substitutions—specifically D-Ala at position 2, Gln at position 8, Ala at position 15, and Leu at position 27—the peptide maintains high conformational stability and receptor affinity while resisting metabolic inactivation. As a target of interest in endocrinology and physiological research, cjc 1295 dac is evaluated for its capacity to maintain basal stimulation of somatotroph cells in the anterior pituitary gland, inducing prolonged synthesis and secretion of endogenous growth hormone and subsequent elevation of circulating Insulin-like Growth Factor 1 (IGF-1).

Because of its distinct pharmacokinetic profile, researchers frequently select this compound over unmodified GHRH fragments when studying long-term signaling dynamics without requiring high-frequency dosing schedules in animal protocols. For precise laboratory investigations, standardized sourcing of high-purity cjc 1295 dac peptide is essential to eliminate analytical noise caused by truncated sequences or residual synthesis impurities.

Mechanism of Action: GHRH Receptor Affinity and Albumin Conjugation

At the cellular level, CJC 1295 DAC functions as a selective agonist at the growth hormone-releasing hormone receptor (GHRH-R), a seven-transmembrane G-protein coupled receptor situated primarily on pituitary somatotrophs. Activation of GHRH-R stimulates the Gαs subunit, driving adenylyl cyclase activity and increasing intracellular cyclic adenosine monophosphate (cAMP). This intracellular signal cascade triggers protein kinase A (PKA) phosphorylation pathways, culminating in transcription factor activation, GH gene expression, and regulated exocytosis of GH granules.

The defining characteristic of the cjc 1295 dac molecule is its DAC technology, which specifically targets the free thiol on Cys34 of circulating albumin. Unlike native GHRH(1-29) which undergoes rapid N-terminal cleavage by DPP-IV, the albumin-bound conjugate preserves the bioactive N-terminal sequence required for receptor interaction while physically restricting access to proteolytic enzymes. In vitro binding assays demonstrate that this bioconjugate retains potent activation of GHRH-R downstream pathways without altered target specificity.

Preclinical studies indicate that sustained activation of GHRH-R by CJC 1295 DAC elevates systemic IGF-1 levels in a dose-dependent manner. IGF-1, primarily synthesized in hepatocytes under GH control, serves as the central mediator for downstream physiological processes such as nitrogen retention, cellular protein synthesis, and cellular proliferation models. Detailed mechanism breakdowns are available across our comprehensive peptide research hub.

Comparative Analysis: CJC 1295 DAC vs. Non-DAC Analogs and GHRPs

Evaluating secretagogue behavior across different structural classes requires analyzing half-life, receptor targets, and secretion patterns. The key distinction between CJC 1295 DAC and non-modified counterparts centers entirely on pharmacokinetic duration and secretion profile.

While CJC-1295 No DAC (often designated Mod GRF 1-29) lacks the bioconjugating maleimide linker and exhibits a biological half-life of 30 minutes, CJC 1295 DAC persists in circulation for multiple days. Early GHRH analogs like Sermorelin mimic native GHRH pulse dynamics over brief windows, whereas Tesamorelin incorporates a trans-3-hexenoic acid modification tailored for specialized metabolic research. In contrast, ghrelin receptor agonists such as Ipamorelin target the growth hormone secretagogue receptor (GHS-R1a) via an independent pathway. Researchers evaluating synergistic signaling mechanisms often co-examine GHRH analogs alongside GHS-R agonists to assess dual-receptor somatotroph activation in vitro.

Comparative preclinical investigations demonstrate that short-acting GHRH analogs preserve pulsatile GH releases, whereas CJC 1295 DAC creates a sustained baseline elevation of GH and IGF-1. Selection between these models depends on whether the experimental model targets continuous receptor engagement or discrete episodic signaling bursts.

Preclinical Research Findings: Downstream Signaling and Tissue Models

In animal models, continuous somatotroph stimulation via CJC 1295 DAC has provided substantial data regarding systemic tissue remodeling and metabolic regulation. Rodent studies evaluating muscle tissue homeostasis demonstrate that sustained GHRH-R activation accelerates amino acid uptake and protein accretion via activation of the Akt/mTOR signaling cascade downstream of IGF-1 receptor engagement.

Further research in preclinical lipid metabolism models indicates that persistent GH secretion enhances lipolysis by upregulating hormone-sensitive lipase (HSL) activity and decreasing adipocyte triglyceride storage. These metabolic shifts occur without altering glucose transporter expression, though long-term exposure protocols closely monitor glucose tolerance parameters due to the counter-regulatory nature of growth hormone on insulin signaling.

In vitro connective tissue and chondrocyte cultures exposed to serum containing CJC 1295 DAC demonstrate elevated collagen type I and collagen type III mRNA expression. These findings suggest that continuous growth factor signaling supports extracellular matrix remodeling and tissue repair kinetics in vitro, providing a solid theoretical foundation for further structural tissue investigations.

Quality Verification Criteria: HPLC, Mass Spectrometry, and Endotoxin Standards

Maintaining experimental reproducibility requires strict analytical validation for every synthetic peptide lot. Because trace chemical impurities or residual synthesis byproducts can disrupt cell culture viability and alter receptor binding kinetics, rigorous quality assurance standards must be met prior to laboratory deployment.

Every batch of research peptides supplied by PX1 Research undergoes rigorous testing in an ISO 17025 accredited laboratory to verify identity and chemical purity. Analytical protocols include:

• Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) ensuring purity exceeding 99%. • Electrospray Ionization Mass Spectrometry (ESI-MS) to verify precise molecular weight and sequence integrity. • Limulus Amebocyte Lysate (LAL) testing to confirm endotoxin levels strictly below <0.5 EU/mg. • Certificate of Analysis (COA) detailing lot-specific analytical data accessible for institutional audit.

All products are USA-manufactured in GMP-compliant facilities and shipped with complete lot traceability. Fast, reliable handling from our CA and AZ facilities ensures immediate dispatch for time-sensitive assay schedules.

Laboratory Reconstitution and Handling Protocols

Lyophilized CJC 1295 DAC requires standard sterile laboratory handling protocols during reconstitution to preserve molecular structure and prevent hydrolysis or aggregation. The peptide matrix is highly sensitive to temperature fluctuations, mechanical shear stress, and rapid pH shifts.

Reconstitution should be performed using sterile bacteriostatic water containing 0.9% benzyl alcohol for multi-use laboratory applications, or sterile 0.9% sodium chloride solution for immediate single-assay applications. Diluent should be introduced down the glass inner wall of the vial rather than sprayed directly onto the lyophilized cake. Gentle swirl mixing is recommended; high-speed vortexing must be avoided as mechanical agitation can induce protein denaturation and peptide aggregation.

For quantitative cell culture work, researchers should calculate target molarities based on the specific net peptide content indicated on the batch-specific COA rather than gross lyophilizate weight. Working stock solutions should be aliquoted into polypropylene microcentrifuge tubes to prevent adsorption loss to glass containers during repeat pipetting steps.

Storage Parameters and Stability Guidelines

To maintain structural integrity and prevent oxidative degradation of amino acid residues, proper storage parameters must be enforced immediately upon receipt of the lyophilized material.

Lyophilized cjc 1295 dac powder should be stored at -20°C for short-term preservation or -80°C for long-term storage, protected from light exposure and ambient humidity. When stored under these conditions, the un-reconstituted peptide remains stable for up to 24 months without significant loss of purity.

Following reconstitution, liquid stock solutions should be refrigerated at 2°C to 8°C and utilized within 14 to 28 days depending on the reconstitution vehicle. For extended research timelines involving reconstituted stock, aliquots should be flash-frozen at -80°C. Repeated freeze-thaw cycles must be rigorously avoided as freeze-thaw stress induces peptide cleavage and hydrophobic aggregation. institutional labs sourcing through our PX1 wholesale portal receive specialized handling documentation for bulk cold-chain storage.

Institutional Procurement and Compliance

PX1 Research provides institutional laboratories, academic research departments, and corporate R&D divisions with verified chemical reagents for controlled in vitro and animal studies. All products sold by PX1 Research are strictly designated for laboratory research use only and are not intended for human or animal therapeutic, diagnostic, or clinical applications.

Every shipment originates from our domestic CA and AZ distribution centers with same-day shipping available for orders processed Monday through Friday before cut-off times. Qualified institutional buyers seeking larger volumes or custom synthesis specifications can consult our dedicated wholesale department for batch-allocated supply and volume pricing parameters.